Guardant Health Engager | In-Person Event

Thursday 20th October, 2022  | 6.00pm - 8:00pm GMT | Free-to-Attend

London, UK

guardant

Clinical Implications of Novel Immuno-Oncology Biomarkers

The Guardant Health Engager is an exclusive 2-hour networking event designed for BioPharma Directors, Heads & VPs working in the Translational Medicine and Companion Diagnostics space looking to stay ahead of the curve and develop the next generation of cancer therapeutics.

Discussing the emergence of multi-omics techniques when studying tumour-immune interactions, as well as focusing on the development of methylation data, this is your chance to dive deep into the clinical implications and the utility of novel biomarkers to take your diagnostic tool to a companion diagnostic approval.

With leading oncology experts joining us to provide their opinion on different liquid diagnostic approaches, do not miss out on successfully strengthening and advancing your precision medicine pipelines!

With an insightful panel discussion among key opinion leaders followed by complimentary appetizers and drinks, this is a date not to be missed!

Please Note: This event is taking place in-person only (London, UK) and online attendance will not be available.

Your Expert Speakers:

Dr. Clara Montagut

Head of Gastrointestinal Cancer

Hospital del Mar

Dr. Peter Schmid

Professor of Cancer Medicine

Cancer Research UK

Dr. Sanjay Popat

Consultant, Medical Oncologist

The Royal Marsden

Iris Faull

Senior Director of Medical Affairs

Guardant Health

More Speakers to be Announced Soon!

Reserve Your Free Seat By Filling Out the Form Below:

Please Note: This event is taking place in-person only, and online attendance will not be available.

This event is reserved for decision makers and senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch upon registering to confirm or decline your place based on the mentioned criteria.

Please Note: This event is taking place in-person only (London, UK) and online attendance will not be available.

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers

Agenda

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

6:35 pm Immuno-Oncology in Early Stage & Advanced Stage CRC

6:45 pm Immuno-Oncology in NSCLC: Current Status & Future Steps

6:55 pm Immuno-Oncology in Triple Negative Breast Cancer & Future Perspectives for Other Subtypes

7:05 pm Panel Discussion: Clinical Implication of Novel Immuno-Oncology Biomarkers

Synopsis

  • Addressing the different challenges and advantages of novel liquid diagnostic approaches
  • Discussing large opportunities in the Immuno-Oncology field when it comes to developing drugs with high efficacy in both early and late-stage cancer
  • Unravelling the necessary steps to take a diagnostic tool all the way through to companion diagnostic approval

7:30 pm Networking Session

Synopsis

This is an informal and exclusive networking opportunity for you to engage with biopharma leaders to discuss how to advance the Liquid Biopsy space!

8:00 pm End of Guardant Health Engager

About Guardant Health:

guardant

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, Guardant Reveal™ test for early-stage cancer patients, and Guardant Shield for colorectal cancer screening.

www.guardanthealth.com